Introduction
This publication along with two others, which deal with the same additives in the same assessment program (Simms et al., 2019; Stabbert et al., 2019) , presents the results of the clinical assessment of thirteen tobacco additives as a single additive or in form of a mixture. These additives have been listed by the European Commission in the Priority List established by the Commission Implementing Decision (EU) 2016/ 787 (European Commission, 2016) . Manufacturers and importers of cigarettes and Roll Your Own (RYO) tobacco containing an additive that is included in this Priority List are required to carry out comprehensive studies (European Union, 2016) . These studies should examine for each of these priority additives whether they:
"(a) contributes to the toxicity or addictiveness of the products concerned, and whether this has the effect of increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree; ….
(c) facilitates inhalation or nicotine uptake;
… "
In our study, two distinct end points were investigated, namely measuring plasma nicotine pharmacokinetics as a measure of nicotine uptake, and analyses of changes in smoker puffing behavior as a measure of cigarette smoke inhalation. This is in line with the recommendation made by SCHEER (SCHEER, 2016) regarding nicotine analysis as a biomarker of exposure in humans. Although there have been discussions on potential additional addictiveness tests for additives, further investigations of such methods have led the Priority Additives Tobacco Consortium to conclude that there are currently no https://doi.org/10.1016/j.yrtph.2019.02.012 Received 26 November 2018; Received in revised form 13 February 2019; Accepted 19 February 2019 other alternative tests that would provide meaningful information on the addictiveness potential of the priority additives (Simms et al., 2019) .
The results presented here refer to the plasma nicotine pharmacokinetics and smoking behavior of regular smokers when smoking cigarettes with and without additives on a comparative basis. Both endpoints are regarded as useful indicators to obtain quantitative data that allow measurement of the impact of cigarette modifications on the facilitation of cigarette smoke inhalation and nicotine uptake (Carter et al., 2009; Fearon et al., 2017; Vas et al., 2015) .
Further in-depth information on the background of this assessment is presented in the lead publication (Simms et al., 2019) .
Materials and methods

Tobacco additives
The Priority List specifies 15 additives subject to enhanced reporting obligations. Two of them are not covered by this publication: Diacetyl and Titanium dioxide. The four lead companies originally forming the consortium (PMI, JTI, Imperial and BAT) resolved to exclude diacetyl from testing as they do not use this additive in their cigarettes or RYO products. Titanium dioxide is only applied to the cigarette filter material as a whitening agent and is not released during the cigarette consumption, as it is not combusted. In the opinion of a scientific committee serving the EU, there is inconclusive and insufficient data for 10 additives regarding their potential to add to the addictiveness of tobacco smoke and their ability to facilitate inhalation or nicotine uptake (SCENIHR, 2010; SCHEER, 2016) CAS 2216 -51-5, 15356-60-2, 89-78-1, 1490 These 10 additives were tested as single additives in our study. In addition, 8 of them were tested in an additive mix together with 3 other additives of the Priority List (Mix 3):
Geraniol CAS 106-24-1 Guar gum CAS 9000-30-0 Maltol CAS 118-71-8
The additives were purchased using the usual manufacturing supply process. All food grade ingredients were certified to be compliant with the requirements of the European regulation or equivalent obligations (European Union, 2008) . Further information on the additives can be found in the lead publication (Simms et al., 2019) .
Experimental cigarettes
The cigarettes were manufactured by British American Tobacco Germany within the parameters of those sold in the EU. The cigarettes were high speed machine-made as per standard commercial cigarette production, using a typical American blend of tobacco, i.e., filter cigarettes with 60% Virginia, 28% Burley, and 12% Oriental tobacco. 15.1% of the tobacco used during manufacture was in form of expanded tobacco and 13.6% was in the form of cut rolled stems. The type of ventilated filter used consisted of a 27-mm mono acetate tow. All cigarettes manufactured for this study were individually coded to prevent any potential mix-up during testing. The cigarettes were packed as conventional retail cigarettes in 20-cigarette card boxes wrapped in polypropylene to prevent losses of moisture or additives. Each pack was clearly labelled on the outside with the manufacturing code.
Additives were added to the tobacco during the standard process of cigarette manufacturing. The additive levels added to the cigarettes were based on the Quantity Not Exceeded (QNE) level used by the steering committee companies (BAT, Imperial Tobacco, JTI, PMI), i.e., the highest concentration used in any of their products manufactured for sale in the EU. This concentration is referred to as the "Max" level in this study.
According to the study design, 12 experimental cigarettes were assessed: (1 additive-free reference cigarette and 11 test cigarettes: 10 cigarettes with a single additive added at the QNE and 1 cigarette with a mix of 11 additives). Additive levels are presented in Table 1 .
Objectives
The primary objective of this study was the assessment of nicotine pharmacokinetic (PK) parameters when smoking cigarettes containing the above-mentioned tobacco additives, i.e., maximum nicotine concentration (C max ), time to reach maximum nicotine concentration (T max ), and the area under the nicotine plasma concentration time curve from time zero to the last measurable concentration (AUC 0-last ).
The secondary study objective was the assessment of smoking behavior as total number of puffs, average puff duration, average puff volume, time smoke held in mouth between puff and inhalation (mouth hold), average inhalation depth, average volume inhaled per puff (inhalation volume), and average volume exhaled per puff (exhalation volume). Definitions for these terms are provided by Gregg et al. (2013) .
Participants
In total, 48 healthy subject smokers (48% females and 52% males) with an age range of 21-54 years and a smoking history of at least 3 years prior to the start of the study were recruited. Their health status was confirmed according to the agreed study inclusion criteria: medical history, physical examination, vital signs assessment, 12-lead ECG, Remarks: * = test cigarettes with single additive.
M. McEwan, et al. Regulatory Toxicology and Pharmacology 104 (2019) 29-38 clinical laboratory evaluations, lung function tests, body mass index of 18.5-30.0 kg/m 2 , and body weight exceeding 52 kg (males) and 45 kg (females). The mean Fagerström Index of the study subjects was 5.9 (standard deviation 1.8), characterizing them as moderate (score 4 to 6) to high dependence (score 7 to 10) smokers. Exclusion criteria consisted of 24 conditions. 40 subjects completed the study per protocol.
Overall study design and plan
The study was performed by the independent Contract Research Organization Celerion in Northern Ireland in compliance with its Standard Operating Procedures (SOPs). The study was conducted in compliance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice (International Council for Harmonization ICH E6 Guideline for Good Clinical practice) as well as local laws and regulations. The study was registered on the clinicaltrials.gov website (NCT03272295).
The study was a single-center, controlled, double-blind study utilizing a randomized, crossover, incomplete block design in which subjects smoked 7 different study cigarettes assigned from a total of 12 different study cigarettes (an additive-free reference cigarette plus 11 different test cigarettes). Subjects were randomized to 1 of 2 study arms. In each study arm, subjects were further randomized to 1 of 6 sequences and received the additive-free reference cigarette twice and 6 test cigarettes once, over a total of 8 study visits as shown in Table 2 . A minimum of 20 subjects were required to smoke each study cigarette. Each study visit followed the same schedule of events. All subjects were required to abstain from using cigarettes or any nicotine product use for 12 h prior to each visit. At each Admission, it was confirmed that the subjects continued to meet all Screening inclusion/exclusion criteria. This was followed by smoking of a single assigned test product and blood draws for the PK assessment in the morning of each visit. In the afternoon the smoking behavior assessment was carried out with a single use of the same test product. For each subject, 1 study cigarette was assessed at each study visit with a minimum of 36 h between study visits. A schematic of the study design is presented in Fig. 1 .
During the study visits, subjects only used the study cigarettes assigned to them. Subjects were reminded of the dangers of smoking prior to enrolment onto the study and that they were free to voluntarily quit smoking and/or withdraw from the study at any time. Between visits, subjects were free to resume their usual smoking habit except for the required period of smoking and nicotine use abstinence prior to each visit. Subjects were instructed to abstain from using any nicotine products for a minimum of 12 h prior to attending each visit.
Subjects arrived at the clinic first thing in the morning for admission where it was confirmed that they continued to meet all screening inclusion/exclusion criteria including an exhaled carbon monoxide breath analysis (< 15 ppm). The pharmacokinetic assessment required the subject to smoke a single cigarette ad libitum. Blood samples were collected for plasma nicotine analysis at specific time points prior to, during, and after the single product use. Following the smoking behavior assessment where the subjects again were required to smoke a single study product ad libitum, the subjects were discharged from the clinic until the next study visit.
For practical reasons, assessment of study cigarettes was divided between 2 groups of subjects: Study Arm A or B. This was to limit the subject burden in terms of the number of study visits and the total amount of blood drawn from each subject. In study arm A, the subjects smoked the additive-free reference cigarette on two occasions and the cigarettes with the first 5 additives listed in Table 1 once. In study arm B the subjects also smoked the additive free cigarette on two occasions as well as the cigarettes with the other additives.
The study was divided into 4 enrolment groups to facilitate study conduct. Each enrolment group was as balanced for age and gender as far as practicable and contained approximately the same number of subjects from the respective arms.
Subjects attended a screening visit within 28 days prior to the first study visit (visit 1). Subjects attended 8 single day study visits of approximately 6-8 h in duration. There was a minimum of 36 h between each visit. After completion of PK and smoking behavior assessments at visit 8, the subjects were discharged from the study. A post-study follow-up assessment was conducted via telephone 5-7 days after discharge.
Smoking behavior measurements
Smoking behavior measurements included puff volume, puff duration, number of puffs, total puff volume, mouth hold duration, inhalation volume, and exhalation volume. Measurements were performed using a smoking behavior system (SBS) as described and characterized The mixed model includes product sequence within study arm, study product, period, study arm, and subject nested within product sequence as a random effect. Parameters are log-transformed prior to analysis. p-values were only reported for AUC 0-last and C max Geometric LS Mean Ratio = 100*(test/reference).
T max values are presented as median (min, max).
Puff number values are presented as arithmetic mean (min, max). McEwan, et al. Regulatory Toxicology and Pharmacology 104 (2019) 29-38 by Vas and coworkers (Vas et al., 2015) . The SBS is a small device developed to minimize any influence on smokers' behavior and incorporates a puffing and respiratory topography measurement system coupled to a data acquisition and transfer unit. The SBS provides a realtime profile of the flow and duration of puffing, post-puff inhalation and exhalation topography, thereby capturing the complete smoking behavior cycle at a resolution of 25-Hz. Puffing analysis was measured by a pressure transducer and an LEDphotometer (660 nm). The unidirectional pressure transducer records pressure changes across an orifice (2 mm), which are proportional to the square of the flow rate. The photometer records light absorption by the smoke aerosol and this is directly related to the quantity of smoke. Respiratory topography analyzer is similar in design to the puffing analyzer, but has an internal mouthpiece bore of 14 mm and contains a bidirectional pressure transducer that detects both positive and negative pressure change across a larger orifice (10 mm) to accommodate the higher flow rates in both directions (volumes inhaled and exhaled). In addition, the respiratory analyzer is heated to 65°C to prevent condensation of water from the smoker's breath onto the optics of the LED and photo-detector.
Nicotine pharmacokinetic measurements
Plasma samples were collected at multiple time points up to 240 min (at −5, 1, 2, 3, 4, 5, 6, 7, 8, 15, 120, 180 and 240 min) during and after smoking the test and additive-free reference cigarette, to evaluate nicotine PK. 'Plasma samples were sent on dry ice for nicotine analysis to Celerion Bioanalytical Services (Lincoln, NE, USA.). An aliquot of each plasma sample containing the analyte and internal standard was extracted using a solid phase extraction procedure. The extracted samples were analyzed by an HPLC equipped with an AB SCIEX API 4000TM triple quadrupole mass spectrometer using an ESI source.
Statistics
All endpoints were presented as arithmetic or geometric means and standard deviations or coefficients of variation, respectively, depending on whether they are considered normal or log-normally distributed. Descriptive statistics also include minimum, maximum, and median by product and timepoint when appropriate.
For the primary objective, the nicotine pharmacokinetic parameters (C max and AUC 0-last ) were examined by statistical comparison of the estimates for the test cigarettes with that of the additive-free reference cigarette, as well as between the first and second use of the reference cigarette. Both log-transformed parameter estimates were evaluated separately in a linear mixed-effects analysis of variance (ANOVA) model with study arm, product sequence, period, product, study arm by product interaction as fixed effects and subject nested within arm, and product sequence as random effects. Geometric least-squares mean (LS Means) values were presented for test and reference products. The difference in the log values and lower and upper 95% CI were backtransformed (exponentiated) and expressed as a percent resulting in the mean ratio and corresponding 95% CI for test/reference cigarettes.
For the secondary objective, the smoking behavior parameters (total number of puffs, average puff duration, average puff volume, time smoke held in mouth between puff and inhalation, average inhalation depth, average volume inhaled per puff, and average volume exhaled per cigarette) were examined without formal inferential statistical comparisons of the estimates for the test cigarettes with the reference cigarette. No statistical comparison was performed due to the lack of significant differences between the pharmacokinetic parameters for all test cigarettes and the reference cigarette. Only descriptive statistical calculations were performed.
All statistical tests were performed at a significance level of α = 0.05.
Results
Safety
There were no Serious Adverse Events (SAEs) reported in this study and no subjects were discontinued due to Adverse Events (AEs). Overall, 21 (44%) subjects experienced a total of 46 AEs in this study. Dizziness and headache were the most frequently reported events. The majority of AEs were mild in severity and considered not related to study products by the PI. There were no remarkable findings in the safety assessments for AEs, vital signs, ECGs, clinical laboratory tests, or physical examinations in the study.
Pharmacokinetics
Summary data for the pharmacokinetics parameters are shown in Table 3 . These data show the T max , C max and AUC 0-last for the test and reference cigarettes. The T max is similar for all cigarettes with a time of between 6 and 7 min. Whereas the plasma nicotine levels as measured by the C max range from 14.33 ng/mL for the test cigarette with fenugreek extract and 18.41 for the test cigarette with sorbitol compared with a level of 16.09 and 17.30 ng/mL for the additive-free reference Fig. 2 . Arithmetic mean (95% CI) plasma nicotine concentration-time profiles following the overall smoking of additive-free reference cigarette and the cigarette with the addition of 1% cocoa powder.
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Regulatory Toxicology and Pharmacology 104 (2019) 29-38 cigarette smoked by Arms A and B respectively. For the AUC 0-last this ranged from 21.84 to 24.59 ng*hr/mL for the menthol cigarette and the cigarette with cocoa powder respectively. Whereas the AUC 0-last for the additive-free reference cigarette ranged between 24.26 ng*hr/mL for Arm A and 23.66 ng*hr/mL for Arm B. The average puff count was 15.1 for the single use of the cigarette with fig juice concentrate with the additive-free reference cigarette being puffed on average 14.5 times by Arm A and 14.2 times by Arm B. The plots of the plasma nicotine concentrations as a function of time gave nearly identical curves. The plots for those that gave the largest deviation in AUC 0-last from the respective additive-free reference cigarette are presented in Figs. 2-4. The test cigarette with the addition of menthol resulted in an AUC 0-last that was 7.6% lower than the additive-free reference cigarette. Whereas, the cigarette with the addition of cocoa had an AUC 0-last that was 1.3% higher than the additive-free reference cigarette. In the case of Mix 3 this gave an AUC 0-last that was 3.5% higher than the additive-free reference cigarette. For all test cigarette products both C max and AUC 0-last were not statistically significant, when compared to the data obtained from smoking the additive-free reference cigarette. Figs. 2-5 show the mean plasma nicotine concentration time profiles for all of the test cigarettes along with the additive-free reference cigarette.
Smoking behavior
Summary data for the smoking behavior parameters measured are shown in Table 4 . For smoking behavior parameters total number of puffs for the additive-free reference cigarette ranged from 18.5 in Arm A to 18.1 puffs in Arm B. For the test cigarettes total number of puffs ranged from 16.5 puffs for the test cigarette with glycerol and 19.2 puffs for the test cigarette with menthol. Puff duration was similar for all the cigarettes with the highest value for the test cigarettes being 2.45 s for propylene glycol and the lowest being 2.22 s for cocoa powder, with the additive-free reference cigarette giving values of 2.3 s for Arm A and 2.37 s for Arm B. The average puff volume ranged between 65.06 mL and 73.16 mL for the test cigarettes and 68.24 and 70.59 mL for the additive-free reference cigarettes. Prior to inhalation, the smoke was held from between 0.86 and 1.0 s for the test cigarettes while mouth hold was 0.98 s for Arm A and 0.88 s for Arm B. This was followed by a mean inhalation depth of between 0.91 and 1.1 L for the test cigarettes and 0.996 and 1.17 L for the additive-free cigarette smoked by Arm A and Arm B respectively. M. McEwan, et al. Regulatory Toxicology and Pharmacology 104 (2019) 29-38 Fig. 5. Arithmetic mean (95% CI) plasma nicotine concentration-time profiles following the overall smoking of additive-free reference cigarette and the cigarettes with the addition of carob bean extract, fenugreek extract, fig juice concentrate, glycerol, guaiacol, liquorice extract powder, propylene glycol, and sorbitol.
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Hypotheses regarding tobacco additives
General hypotheses
Six of the tested additives (carob bean, cocoa, fenugreek, fig, guar gum, and liquorice) constitute complex botanicals, primarily composed of carbohydrates, protein, water and other components. SCENIHR hypothesized that the combustion of sugars from these botanicals, sorbitol, and glycerol may lead to an increase in aldehydes, especially acetaldehyde, that could inhibit the enzyme mono-amine oxidase (MAO) and "act synergistically with nicotine to enhance addiction potential". This is due to MAO-A, a MAO enzyme sub-type, which has been linked to enhanced dopamine activity and thus an increased reinforcement behavior (SCENIHR, 2010) . This assumption has been shared by others (Talhout et al., 2007) . However, based on chemical/ physical considerations as well as on a broad data base with chemistry data for commercial cigarettes an effect of sugars on acetaldehyde levels in cigarette smoke seems unlikely (Seeman et al., 2003) . Equally, the bioavailability of acetaldehyde from tobacco smoke seems to be too low to exert any pharmacological effect (Seeman et al., 2002 ). This conclusion is in accordance with animal studies, where the direct infusion of acetaldehyde together with other smoke constituents did not enhance nicotine self-administration even at up to a dose ten times higher than expected to be applied by cigarette smoke (Smith et al., 2015) . Furthermore, epidemiological studies (108 treatment groups and 108 control groups) in smokers of cigarettes with and without tobacco additives have shown no differences in the cessation rates of smokers (Sanders et al., 2012) .
SCENHIR hypothesized further that the botanicals used as tobacco additives themselves have a certain flavor or may generate during combustion some compounds with such organoleptic properties, these may act "by improving smoke flavour, thereby masking its bitter taste, reducing the harshness of smoking, creating sensory cues, which all could contribute to the optimisation of nicotine dosing and enhance abuse potential" (SCENIHR, 2010) . The study presented here shows that the addition of the additives did not alter the smoking behavior as an indicator for a change in the sensory properties of the smoke. Furthermore, with the exception of menthol (at the max level 1.2% only, not at the low level 0.6%), none of the additives in the unsmoked cigarettes generated a characterizing flavor that might have masked the original taste of the smoke (E. Chambers; in preparation to be published in a separate journal). Also, an optimisation of nicotine dosing can be excluded as this study has demonstrated that nicotine uptake and pharmacokinetics were not altered by the priority tobacco additives.
In earlier publications some authors hypothesized that tobacco additives may cause an increase in smoke pH, which in turn would increase the free-base portion of nicotine relative to the protonated conjugate acid, enhance the volatility of nicotine, and finally facilitate the uptake of nicotine through biological membranes into the body (Ashley et al., 2009; Pankow et al., 2003; SCHEER, 2016 ). An effect of the pH on nicotine absorption is well established for the oral mucosa (Tomar and Henningfield, 1997) . However, considering the buffering capacity of the lining fluid of the lung, this effect is highly unlikely to play any effect in inhalation uptake of nicotine. In the meantime, most authors agree with the opinion of SCENHIR: "[…] due to the high buffer capacity of the lining fluid in the lungs it is uncertain if more nicotine is absorbed with higher smoke pH … -… In view of the buffer capacity of the body fluids involved (saliva, lung lining fluid), the presence of such an effect is doubtful" (McKinney et al., 2012; SCENIHR, 2010; Seeman and Carchman, 2008; van Amsterdam et al., 2011; Willems et al., 2006) . Furthermore, this conclusion has to be seen relative to the finding that greater than 90% nicotine in mainstream smoke is deposited in the respiratory tract from cigarettes, regardless of design (Armitage et al., 2004) . Once deposited within the lower respiratory tract (the main site of nicotine absorption), nicotine is absorbed rapidly, regardless of the n = Number of observations used in the analysis this is reported in the study arm column unless otherwise stated. Parameters are presented as arithmetic mean (SD).
M. McEwan, et al. Regulatory Toxicology and Pharmacology 104 (2019) 29-38 acid-base nature of the particles (Seeman, 2007; Seeman and Carchman, 2008) . For certain of the priority tobacco additives, SCENHIR expressed a concern that their constituents have pharmacological properties that might change smoking behavior, nicotine uptake, and finally add to the addictiveness of tobacco smoke (SCENIHR, 2010) . This aspect will be addressed individually for the different additives in the following chapter.
Individual hypotheses regarding tobacco additives
Theobromine is a bronchodilating substance that is found in cocoa powder. The pharmacological effect of theobromine has been known for several decades (Simons et al., 1985) . Thus, a concern was expressed that the addition of cocoa as a tobacco additive may contribute to the absorption of nicotine when smoking tobacco (Bates et al., 1999; Fowles, 2001) . A cautious estimate, however, conducted by Klus shows that the level of theobromine exposure to a smoker of 40 cigarettes per day is more than 100 times less than the level of theobromine shown to have bronchodilatory effects (Klus et al., 2012) . In the second publication of this series ) the transfer rate of theobromine from the cocoa powder in the tobacco blend into the smoke was determined to be 4.2, 4.5, and 5.1% (Low, Max, and Max Plus addition level). These values are significantly lower than reported in an internal company document (Zaidi, 1974) . The reason for this discrepancy is obviously that pure theobromine was injected into the tobacco and not given in the form of cocoa powder. At the Max addition level, we found 6.51 μg theobromine/cigarette in the smoke. Assuming a cigarette consumption of 40 cigarettes/day, the daily uptake would be 260 μg theobromine. Pharmacological effective doses of theobromine start at approximately 500 mg/day (Simons et al., 1985) . Thus, a pharmacological effect of coco powder as a tobacco additive can be clearly excluded. This is in line with the conclusions published in the meantime by several institutions (RIVM, 2002; SCHEER, 2016) .
Glycyrrhizic acid is a substance that is found in liquorice and has a weak spasmolytic effect when taken orally. In the context of tobacco additives, without providing any evidence, it was stated that glycyrrhizic acid has a bronchodilating effect (Bates et al., 1999) . In fact, there are no medical applications that use this substance for bronchodilation. Already in an extensive survey on liquorice as a tobacco additive published by the Institute for Public Health and Environment of the Netherlands (RIVM) the authors concluded "The statement that glycyrrhizin acts as a bronchodilatator could not be verified in the currently available literature" (van Andel et al., 2003) . Nevertheless, this potential is still reported, e.g., in the fact sheet created by the German Cancer Research Center (Nair, 2012) or in the report by SCHEER on comprehensive studies on tobacco additives for consideration by the European Commission (SCHEER, 2016) . In our studies, we could not detect any glycyrrhizic acid in the smoke . Accordingly, there is neither a bronchodilating effect of glycyrrhizic acid nor an exposure.
Menthol produces a seeming cooling sensation when in contact with the skin or oral membrane (Eccles, 1994) . Furthermore, it has been reported that menthol has some short term local analgesic properties when applied on the oral mucosa in a capsaicin-induced irritation model at menthol concentrations that showed weak or moderate irritation (Green and McAuliffe, 2000) . However, the levels of menthol that elicited this effect are unlikely to manifest at the levels of menthol exposure through cigarette smoking (Heck, 2010) . Nevertheless, a concern was expressed that the addition of menthol as a tobacco additive may facilitate the inhalation of smoke by reducing the perceived harshness of the tobacco smoke due to these properties (SCHEER, 2016) . In addition, to the fact that data on an analgesic effect of menthol are scarce, human studies do not support any effect on an increased uptake of nicotine. Smokers that had prior experience of smoking both menthol and non-menthol cigarettes, did not show differences in their uptake of nicotine and carbon monoxide in a cross-over study with mentholated and non-mentholated cigarettes (Benowitz et al., 2004) . Salivary levels of cotinine, the major metabolite of nicotine, was not different in a study conducted with smokers of mentholated and non-mentholated cigarettes (Rostron, 2012 (FDA, 2013) .
Limitations
Due to the large number of study cigarettes required to be tested in this clinical study necessitating 8 visits for each subject to complete the study it was agreed that this required a non-confined study design. As the cigarettes used in this study were test products which were only used in the clinical setting it was not possible for the subjects to have a familiarization period with the test products prior to their study visits. While this should have no influence on the absorption rate of nicotine, this could have an impact on the smoking behavior.
Conclusion
The data presented in this publication shows the results of a human clinical study to fulfil the requirements of EU TPD (2014/40/EU) Article 6 (2) that was commissioned by a consortium of 12 tobacco companies to the independent Contract Research Organization Celerion in Northern Ireland. Summarizing, the results of this clinical study indicated that the inclusion of none of the priority additives either as single additive or as part of a mixture, facilitated nicotine uptake. Furthermore, the data did not suggest that differences in the inhalation pattern of cigarette smoke of any of the Priority Additives tested occurred when compared to the additive-free reference cigarette. Finally, by the current state of scientific knowledge, it is concluded that neither the scientific literature nor our study gave circumstantial indications of increased addictiveness for cigarettes containing these additives.
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